Source comparison
Comparison: BPC-157 vs. Current Crohn's Therapies
Mechanism VEGF upregulation, angiogenesis, NO pathway modulation, IL-10 induction Direct TNF-α blockade, systemic immune suppression Topical anti-inflammatory effect in colonic mucosa BPC-157 addresses tissue repair. Biologics address immune dysregulation. Com
This comparison does not assign a generated winner or score.
- Mechanism
- VEGF upregulation, angiogenesis, NO pathway modulation, IL-10 induction
- Direct TNF-α blockade, systemic immune suppression
- Topical anti-inflammatory effect in colonic mucosa
- BPC-157 addresses tissue repair. Biologics address immune dysregulation. Complementary, not substitutive.
- Evidence Base
- Preclinical only. Animal colitis models, no human trials
- Phase III RCTs, decades of clinical use, FDA-approved
- Phase III RCTs, mild-to-moderate disease only
- Anti-TNF drugs have robust human efficacy data. BPC-157 has mechanism plausibility but zero clinical validation.
- Administration
- Subcutaneous injection or oral (unproven bioavailability)
- Subcutaneous or IV infusion every 2–8 weeks
- Oral tablets or rectal suppositories
- BPC-157's injection frequency and optimal route remain undefined.
- Cost
- $80–$150/month (compounded, research-grade)
- $2,000–$6,000/month (brand-name, insurance-dependent)
- $200–$400/month (generic)
- Cost advantage is irrelevant without efficacy data.
- Regulatory Status
- Not FDA-approved for any indication. Research use only
- FDA-approved for Crohn's disease, ulcerative colitis, others
- FDA-approved for ulcerative colitis, off-label for Crohn's
- Using BPC-157 clinically requires understanding it's outside regulatory oversight.